NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1
PR Newswire associated2

Tags

Telix-Pharmaceuticals

More Like This

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

Illuccix® Receives European Approval

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

PR Newswire associated0

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

PR Newswire associated0

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

PR Newswire associated0

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

PR Newswire associated0

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region